Sheppard Mullin Richter & Hampton LLP | USA | 12 May 2023
This week, the Drug Enforcement Administration (“DEA”), in conjunction with the Substance Abuse and Mental Health Services Administration (“SAMHSA”)…
Riker Danzig LLP | USA | 11 May 2023
After loosening the in-person requirements in prescribing controlled substances (“CDs”) during COVID-19, the Drug Enforcement Administration ("DEA")…
Benesch Friedlander Coplan & Aronoff LLP | USA | 4 May 2023
Earlier this year in late February, the Drug Enforcement Administration (DEA) announced proposed rules attempting to change the rules for…
Bradley Arant Boult Cummings LLP | USA | 14 Mar 2023
On March 1, 2023, the Drug Enforcement Administration (DEA) released the proposed rule, "Telemedicine Prescribing of Controlled Substances When the…
Bradley Arant Boult Cummings LLP | USA | 9 Mar 2023
Last week, we wrote about the Drug Enforcement Administration’s (DEA) February 13, 2023 response letter stating that delta-8 THCO and delta-9 THCO -…
McDermott Will & Emery | USA | 28 Feb 2023
On February 24, 2023, the US Drug Enforcement Administration (DEA) issued two proposed rules (the Telemedicine Controlled Substance Proposed Rule and…
Bradley Arant Boult Cummings LLP | USA | 23 Feb 2023
In the summer of August 2022, and again in February 2023, a North Carolina attorney wrote to the Drug Enforcement Administration (DEA) to ask about…
Cote Law PLLC | USA | 20 Feb 2023
In a highly regulated industry, such as controlled substance distribution, having clarity of regulatory requirements facilitates implementation and…
Duane Morris LLP | USA | 16 Feb 2023
On February 13, 2023, the U.S. Drug Enforcement Administration (DEA) published a letter in which it opined that two acetate compounds chemically…
Akerman LLP | USA | 16 Feb 2023
A Florida “resident physician” is someone who has completed their internship and graduated from medical school but is not yet licensed as a Florida…